Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
Fort Lee, NJ, March 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage...
Year: 2023
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
Enrollment Underway in Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March...
Alpha Pro Tech, Ltd. Announces Fourth Quarter and Full Year 2022 Financial Results
Net sales for the fourth quarter of 2022 were $12.2 million, down 7.4% compared to $13.2 million for the fourth...
New Study from Bicycle Health shows tele-OUD treatment associated with reductions in patient risks for relapse
Patient feedback from the standardized Brief Addiction Monitor (BAM) assessment demonstrates reductions in drug and alcohol usage, and other risk...
Microbot Medical Launches Presence in the United Kingdom as Highly Accomplished Consultant Interventional Radiologist Professor Mark W. Little Joins its Scientific Advisory Board as Efforts to Commercialize the LIBERTY® Robotic System Continue to Accelerate
Internationally Recognized Academic Leader Awarded the National Institute for Health Research (NIHR) Research Rising Star Award, and Cardiovascular and Interventional...
NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA
Award recognizes NeuroStar for its significant contributions toward patient wellbeingMALVERN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:...
Accelus Announces FDA 510(k) Clearance of Remi Robotic Navigation System for Use with 2D Fluoroscopy-Based Imaging System
Remi now cleared for use with most commonly used 2D and 3D imaging systems for spine surgeryPALM BEACH GARDENS, Fla.,...
AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease
Growing body of data supports Ampligen’s potential as both a prophylactic and an early-onset therapy against human Ebola virus disease...
GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray
New research released at ACMG Annual Clinical Genetics Meeting reiterates the superiority of exome sequencing’s role in shortening the diagnostic...
Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting
– CD20-targeted GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for...
Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial
Subjects completed 16-week treatment with no significant safety issues Topline results expected in the first half of 2023 SCOTTSDALE, Ariz.,...
Surgalign to Host its 2023 Annual Meeting of Shareholders on June 1, 2023
DEERFIELD, Ill., March 16, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on...
CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call
MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and...
Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023
DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in...
Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder
Company plans to initiate phase I/IIa in-human clinical trials in Q2 2023 Tel Aviv, Israel / Vancouver, Canada, March 16,...
Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)
Pharmanovia to acquire license to GHRYVELIN™from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediatelyTORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE)...
Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Equity Analyst Coverage by Fundamental Research Corp. with a “Buy” Recommendation
Providence, RI, March 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next generation biopharma company, announces initiation...
Isolation of Circulating Tumor Cells with TellDx Platform Reveals Potential Mechanism of Resistance to Immune Checkpoint Blockade in Melanoma
--Interrogation of circulating tumor cells (CTCs) shows downregulation of KEAP1 gene promotes resistance to immune checkpoint blockade in melanoma-- --Study provides...
Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
NORCROSS, Ga., March 16, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3,...
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
DOYLESTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused...